Aurinia Pharmaceuticals Inc. (AUPH - Free Report) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $3.88–$6.38 in the past one-month time frame, witnessed a sharp increase yesterday.
The move came after the company announced that AURORA Phase 3 results for the treatment of lupus nephritis study is on track. It also provided an update regarding at-the-market offerings of its common shares.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Aurinia Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the Medical – Drugs industry may consider a better-ranked stock like Catalent, Inc. (CTLT - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AUPH going up? Or down? Predict to see what others think:Up or Down
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.50% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>